Z62954982
Z62954982 性质
| 储存条件 | -20C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 类白色固体 |
| 颜色 | 白色至米白色 |
| InChI | 1S/C20H21N3O5S/c1-12-7-8-16(10-19(12)29(21,25)26)22-20(24)15-5-4-6-17(9-15)27-11-18-13(2)23-28-14(18)3/h4-10H,11H2,1-3H3,(H,22,24)(H2,21,25,26) |
| InChIKey | OZZQJOAJXMUXCO-UHFFFAOYSA-N |
| SMILES | CC1=CC=C(NC(C2=CC(OCC3=C(C)ON=C3C)=CC=C2)=O)C=C1S(N)(=O)=O |
Z62954982 用途与合成方法
Z62954982 (5-100 μM; 4 hours) reduces the intracellular levels of Rac1- GTP in a concentration-dependent manner,and shows the most potent inhibitory action with an IC 50 of 12.2 μM in Human SMCs.Z62954982 (25 μM; 4 hours) significantly reduces the ratio Rac1-GTP/Rac1 and has the most potent inhibitory action (86.0%) in cultured SMCs.Z62954982 (10-100 μM; 72 hours) causes a concentration-dependent decrease in transendothelial electrical resistance (TER) in both HDMEC and HUVEC monolayers.
Z62954982 (intraperitoneal injection; 10 mg/kg every other day or 20 mg/kg daily; 3 weeks) has no obvious signs of toxicity and decreases both phosphorylation of p38 as well as secreted IL-6 in PASMCs in response to hypoxia in both abr -/- and bcr -/- mice.
| Animal Model: | Male bcr -/- , abr -/- and wt mice (8 to 10-week-old littermates) are exposed to hypoxia (10% O2) or normoxia (21% O2) for 3 weeks |
| Dosage: | 10 mg/kg or 20 mg/kg |
| Administration: | Intraperitoneal injection; 10 mg/kg every other day or 20 mg/kg daily; 3 weeks |
| Result: | Promoted phosphorylation of p38 MAPK and increased IL-6 in Hypoxia in mice. |
Z62954982 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-115376 | Z62954982 | 1090893-12-1 | 1 mg | 473 |
| 2026-09-15 | HY-115376 | Z62954982 | 1090893-12-1 | 5 mg | 1100 |
